SCHEMBL829393

SCHEMBL829393

CCCCCCCCCCc1c[c]ccc1CCCCCCCCCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.43
TYR P14679 2/20 0.42
TP53 P04637 2/20 0.42
CYP3A4 P08684 2/20 0.42
MEN1 O00255 1/20 0.42
ALOX5 P09917 1/20 0.42
MAPT P10636 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KCNH2 Q12809 2/20 0.41
ESR1 P03372 2/20 0.38
ADRA2A P08913 2/20 0.38
ADORA3 P0DMS8 2/20 0.38
TACR2 P21452 2/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4863392 1.00 LIPG (0.43) LIPGTYRTP53CYP3A4MEN1
SCHEMBL4865770 1.00 LIPG (0.43) LIPGTYRTP53CYP3A4MEN1
SCHEMBL1334347 1.00 LIPG (0.43) LIPGTYRTP53CYP3A4MEN1
SCHEMBL828966 1.00 LIPG (0.43) LIPGTYRTP53CYP3A4MEN1
SCHEMBL1335248 1.00 LIPG (0.43) LIPGTYRTP53CYP3A4MEN1
SCHEMBL4868376 1.00 LIPG (0.43) LIPGTYRTP53CYP3A4MEN1
SCHEMBL677099 0.98 LIPG (0.40) LIPGTYRTP53CYP3A4MEN1
SCHEMBL8038723 0.92 LIPG (0.41) LIPGTYRTP53CYP3A4MEN1
SCHEMBL3001599 0.92 LIPG (0.41) LIPGTYRTP53CYP3A4MEN1
SCHEMBL677260 0.92 TYR (0.38) LIPGTYRTP53CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429548-B2 Soluble late transition metal catalysts for olefin oligomerizations III EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-09-30 US claimed
EP-1620447-B1 SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III EXXONMOBIL CHEM PATENTS INC (US) 2007-08-08 EP claimed
US-7161018-B2 Soluble late transition metal catalysts for olefin oligomerizations II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-01-09 US claimed
EP-1513854-B1 SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS EXXONMOBIL CHEM PATENTS INC (US) 2006-11-29 EP claimed
US-20060036049-A1 Soluble late transition metal catalysts for olefin oligomerizations III ZHAO BAIYI 2006-02-16 US claimed
EP-1569751-B1 METHODS FOR PREPARING CATALYSTS EXXONMOBIL RES & ENG CO (US) 2015-10-07 EP disclosed
EP-1718596-B1 CATALYTIC PREPARATION OF SEVERELY STERICALLY HINDERED AMINO-ETHER ALCOHOLS USING A METAL LOADED CATALYST EXXONMOBIL RES & ENG CO (US) 2014-08-27 EP disclosed
US-8288025-B2 High performance polymeric blend membrane materials based on N-heterocycles and acid-base interactions BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-10-16 US disclosed
US-8143438-B2 Hydrogenation processes EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-03-27 US disclosed
CN-1717278-B Process for preparing catalyst EXXONMOBIL RES & ENG CO 2011-07-13 CN disclosed
US-20110082311-A1 Hydrogenation Processes EXXONMOBIL RESEARCH AND ENGINEERING COMPANY 2011-04-07 US disclosed
US-7875742-B2 hydrogenating organic compounds by contacting with hydrogen-containing gas in presence of catalyst which comprises catalytically active metals applied to porous catalyst support; catalytically active metals having been derived via decomposed amine complex of metal on support EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-01-25 US disclosed
US-6916965-B2 Treatment of acid catalysts EXXONMOBIL CHEMICAL PATENTS INC. (US) 2005-07-12 US disclosed
EP-1490172-A1 TREATMENT OF ACID CATALYSTS WITH NITROGEN COMPOUNDS ExxonMobil Chemical Patents Inc. (US) 2004-12-29 EP disclosed
US-20040157732-A1 Treating an activated metalloaluminophosphate molecular sieve with one or more nitrogen containing compounds (aliphatic, aromatic, hetetrocycic or organonitrile compounds) to chemisorb and/or physisorb nitrogen-compound EXXONMOBIL CHEMICAL PATENTS INC. 2004-08-12 US disclosed
US-6756516-B2 Treatment of acid catalysts EXXONMOBIL CHEMICAL PATENTS INC. 2004-06-29 US disclosed
WO-2004046076-A2 HYDROGENATION CATALYST, PREPARATION THEREOF AND HYDROGENATION PROCESSES USING THIS CATALYST EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2004-06-03 WO disclosed
WO-2004045767-A2 METHODS FOR PREPARING CATALYSTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2004-06-03 WO disclosed
WO-2003084661-A1 TREATMENT OF ACID CATALYSTS WITH NITROGEN COMPOUNDS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2003-10-16 WO disclosed
US-20030004056-A1 Treatment of acid catalysts EXXONMOBIL CHEMICAL PATENTS INC. 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082311-A1 Hydrogenation Processes HAO2, HVCN1, AOC3 LIPG 1637/4885TYR 468/4885TP53 4757/4885
US-20060036049-A1 Soluble late transition metal catalysts for olefin oligomerizations III COMT, CD69, SPR LIPG 3770/4885TYR 275/4885TP53 1482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.